You've reached the limit for free Overall Ranking scores. For more information, request a demo.
See CSRHub in Action
You have a total of 10 free searches available.
| Low 0-29 | 30-39 | 40-49 | 50-59 | 60-79 | 80-100 High |
Par has been developing, manufacturing and distributing generic pharmaceuticals since 1978. As of November 2009, the company had 45 ANDAs pending approval, simultaneously moving forward with the development of a line of branded supportive care therapies for AIDS and cancer patients. Since June 2007, the company's proprietary products division, Strativa Phamaceuticals has in-licensed four branded products in development -- Zensana Oral Spray, Loramyc, ONCONASE, and an oral thin film formulation of ondansetron. In recent years, the company introduced generic versions of several major pharmaceutical products, including Inderal LA, TOPROL XL, Flonase, Dostinex, Ultracet, Accupril, Paxil, Prozac, Marinol and Imitrex.
| Ticker: | PRX |
| ISIN: | US69888PAB22 |
| Address: |
300 Tice Boulevard |
| Woodcliff Lake, NJ, 07677, USA | |
| Website: | Par Pharmaceutical, Inc. |
| Phone #: | 845-573-5500 |
| ESG Web Area: | Subscribers Only ? |
| Industry: | Pharmaceutical & Medicine Manufacturing |
We considered many names for our site—in fact we spent our first year and a half under a different name—EkoHub. We liked “Eko” — coming from the Greek word Oikos, related to economy, ecology, and “home” or social concerns. From the beginning, we believed the word “Hub” reflected our desire to be at the center of the sustainability area, providing knowledge, harmony, and consensus among the hundreds of experts judging the ESG performance of companies.